Proactive Investors - Run By Investors For Investors

MaxCyte inks research agreement with Gilead subsidiary Kite Pharma

The AIM-listed bioscience firm said under the agreement Kite would use its Flow Electroporation Technology platform to enable non-viral cell engineering
Cell being injected
Flow Electroporation is used in gene editing and allows almost any molecule to be delivered into a cell

MaxCyte Inc (LON:MXCT) has signed a research agreement with Kite Pharma Inc, a subsidiary of US drugmaker Gilead Sciences Inc (NASDAQ:GILD), to use its Flow Electroporation Technology (FET) platform.

The AIM-listed bioscience firm said under the agreement Kite would use the FET platform to enable non-viral cell engineering.

WATCH: Major announcements for MaxCyte

Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.

Doug Doerfler, president and chief executive of MaxCyte, said Kite would be utilising the firm’s platform to enable gene-editing technologies for the research and development of new therapeutics.

The deal follows a commercial license agreement signed last week between MaxCyte and gene-based medicine maker CRISPR Therapeutics in a move to advance the development of anti-cancer treatments.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Video
November 13 2018

Related Articles

seeds in a bowl
March 07 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives
blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use